Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) released its earnings results on Friday. The company reported $0.16 earnings per share (EPS) for the quarter, Zacks reports. Shionogi & Co., Ltd. had a net margin of 35.53% and a return on equity of 11.95%.
Shionogi & Co., Ltd. Trading Down 9.2 %
Shares of SGIOY traded down $0.70 during mid-day trading on Tuesday, reaching $6.94. The stock had a trading volume of 186,481 shares, compared to its average volume of 211,603. Shionogi & Co., Ltd. has a 52-week low of $6.22 and a 52-week high of $9.11. The business's fifty day moving average is $7.09 and its 200 day moving average is $8.52.
Shionogi & Co., Ltd. Company Profile
(
Get Free Report)
Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.
Recommended Stories
Before you consider Shionogi & Co., Ltd., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shionogi & Co., Ltd. wasn't on the list.
While Shionogi & Co., Ltd. currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
